

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 November 2018 (22.11.2018)



(10) International Publication Number
WO 2018/213113 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2018/032218

(22) International Filing Date:
11 May 2018 (11.05.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/508,510 19 May 2017 (19.05.2017) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **ATWELL, Shane Krummen**; c/o Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **OBUNGU, Victor H.**; c/o Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **VENDEL, Andrew Charles**; c/o Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US).

(74) Agent: **THOBE, Megan N.** et al.; Eli Lilly And Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: **BTLA AGONIST ANTIBODIES AND USES THEREOF**

(57) Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.



WO 2018/213113 A1